Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have many in the pipelines. AIKI, HOTH, finding cure for COVID-19 would be a good one for starters. Any other ones would be good.
$AIKI it has proven better than w.h.o. is touting
$AIKI WHICH ONES ?????
RE;
We need to hear from company, finalized approved products. Hopefully soon!
$AIKI THANK YOU, I WISHED IT DID.
RE;
Hydroxychloroquine has nothing to do with AIKI.
Hydroxychloroquine has nothing to do with AIKI.
We need to hear from company, finalized approved products. Hopefully soon!
Hydroxychloroquine. What about it?
$AIKI READING INFO http://www.Benzinga.com
RE;
Options Trade Ideas from Benzinga
In this market, there's never been a better time to profit with options. Get Benzinga Options: Starter Edition to follow Nic Chahine's high-conviction options trades. Click here to subscribe.
AIkido Pharma is a U.S.-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Aikido Pharma's stock was trading up 5.77% at 92 cents on Thursday during the time of publication. The stock has a 52-week high of $5.52 and a 52-week low of 48 cents.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
$AIKI , THANK YOU FER INFO. YA HAVE DA LINK ?????
RE;
Aikido Pharma Announces Key Progress In Computational Approaches To Identify Virus Treatments, Including Coronavirus
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
July 09, 2020 1:32pm 1 min read Comments
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.
Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.
Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.
Alkido Pharma Inc (AIKI)
0.8529 ? 0.0132 (1.57%)
Volume: 1,062,244 @07/15/20 1:08:58 PM EDT
Bid Ask Day's Range
0.8501 0.8529 0.8267 - 0.853
AIKI Detailed Quote
$AIKI would know name of dat drug ????? hydo something
Aikido Pharma Announces Key Progress In Computational Approaches To Identify Virus Treatments, Including Coronavirus
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
July 09, 2020 1:32pm 1 min read Comments
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.
Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.
Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.
$AIKI IS HOTH ah spinoff from $AIKI ????? WHAT WAS SPINOFF SHARES ?????
RE;
https://www.prnewswire.com/news-releases/aikido-pharma-inc-sets-record-date-for-hoth-distribution-301043157.html
https://www.streetinsider.com/PRNewswire/Hoth+Therapeutics%2C+Inc.%2C+Voltron+Therapeutics%2C+Inc.%2C+%26amp%3B+HaloVax+Announce+Selection+of+the+First+of+Two+Sets+of+Virus+Targeting+Peptides+for+Animal+Testing+in+the+Development+of+a+COVID-19+Vaccine/16782289.html
https://www.prnewswire.com/news-releases/aikido-pharma-inc-sets-record-date-for-hoth-distribution-301043157.html
https://www.streetinsider.com/PRNewswire/Hoth+Therapeutics%2C+Inc.%2C+Voltron+Therapeutics%2C+Inc.%2C+%26amp%3B+HaloVax+Announce+Selection+of+the+First+of+Two+Sets+of+Virus+Targeting+Peptides+for+Animal+Testing+in+the+Development+of+a+COVID-19+Vaccine/16782289.html
$AIKI thank you , $HOTH ????? what they do ?????
Drug approvals could happen. Also HOTH is associated with AIKI.
No, this wasn't the co.
$AIKI,can you give information that you know will make $AIKI $5 or better ?????
$AIKI reading , i got in this morning !!!!!
$AIKI , i updated ibox some.
$AIKI, is this company that has drug that w.h.o. said does not help any wit the coronavirus ?????
i ferget drug name !!!!!
trump was taking the drug and said no side effects ?????
news out friday drug does work & needs more theory !!!!!
$AIKI, NICE REPORE' MY FRIEND !!!!!
$AIKI NICE REVIEW DARE !!!!
It'll go insanely north when AIKI announces the right news!
$AIKI i just started reading on $AIKI
Could be huge!
$AIKI READING YOUR MESSAGE INTERESTING.
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a
sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.
Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the
nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts.
Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides.
These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination,
binding to the spike protein, and finally cell challenge assays with SARS-Cov-2. Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.
"VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease," said Mr. Robb Knie, CEO of Hoth Therapeutics.
"We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic."
Currently, Dr. Peters is utilizing supercomputers as part of the
COVID-19 High Performance Computing (HPC) Consortium through the
Extreme Science and Engineering Discovery Environment (XSEDE),
a virtual system that scientists can use to interactively share computing resources.
The consortium is a private-public partnership that includes the
White House Office of Science and Technology Policy and major tech corporations.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders.
Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19.
To learn more, please visit HTTP://www.hoththerapeutics.com.
Yup! Waiting for the big news move!
$AIKI
https://aikidopharma.com/
https://aikidopharma.com/about/
https://aikidopharma.com/portfolio/
https://aikidopharma.com/portfolio/aml-all/
https://aikidopharma.com/portfolio/pancreatic-cancer/
https://aikidopharma.com/scientific-advisory-board/
https://aikidopharma.com/published-papers/
https://ir.aikidopharma.com/
About
AIkido Pharma Inc. .
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The AIkido Pharma Inc. platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs. Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
$AIKI Spherix Incorporated, a biotechnology company,
focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing
pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
$AIKI AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus PR Newswire (US) - 7/9/2020 1:31:00 PM
AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research PR Newswire (US) - 6/26/2020 10:30:00 AM
$AIKI Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 9:55:07 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/19/2020 6:00:46 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/12/2020 3:21:30 PM
$AIKI Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/8/2020 3:04:29 PM
AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University PR Newswire (US) - 5/28/2020 10:00:00 AM
Alkido Pharma Inc (AIKI)
0.885 ? -0.0451 (-4.85%)
Volume: 5,970,365 @07/10/20 7:59:13 PM EDT
Bid Ask Day's Range
0.87 0.88 0.86 - 0.9544
AIKI Detailed Quote
Share Structure
Market Cap Market Cap
4,488,243
07/09/2020
Authorized Shares
200,000,000
03/02/2020
Outstanding Shares
4,825,549
03/02/2020
https://www.otcmarkets.com/stock/AIKI/security
Thanks! Good luck!
Awesome dd bought some today
Voltron Therapeutics, Inc. And Hoth Therapeutics Initiates Animal Testing Of HaloVax Self-Assembling Vaccine For COVID-19
8:39 am ET July 8, 2020 (Benzinga) Hot Stories Print
Animal Trials to Assess the Effect of Novel Vaccine HaloVax™ Against COVID-19
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targets into preclinical testing, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).
The vaccine is built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the COVID-19 virus, which are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production and accommodate potential changes in the pathogen itself. The selected immunogenic peptides complete the customized COVID-19 vaccine.
https://voltrontx.com/ SPEX/HOTH/VOLTRON have been working together on cures.
You welcome! Good luck!
Thanks for that response. I was trying to determine if it was bullish for the stock. we hit the 200 day Friday and was looking for something to be bullish about.
Followers
|
156
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8287
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Short-term Toxicity Study of DHA-dFdC
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
https://ir.aikidopharma.com/stock-information/
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |